Alnylam Pharmaceuticals, Inc. (ALNY) Analysts See $-1.93 EPS

October 13, 2018 - By Louis Casey

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) LogoInvestors sentiment increased to 1.61 in 2018 Q2. Its up 0.21, from 1.4 in 2018Q1. It improved, as 33 investors sold Alnylam Pharmaceuticals, Inc. shares while 60 reduced holdings. 57 funds opened positions while 93 raised stakes. 92.05 million shares or 3.13% more from 89.26 million shares in 2018Q1 were reported.
American Century invested 0.04% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Kepos Capital Limited Partnership has invested 0.08% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The Maryland-based Proshare Ltd Co has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 137,700 were reported by Capital Ww Investors. Caisse De Depot Et Placement Du Quebec holds 0% or 2,800 shares. Mitsubishi Ufj Tru & Bk accumulated 483,351 shares or 0.08% of the stock. Sumitomo Mitsui Asset Mgmt Communication Limited reported 19,432 shares. Grp Inc One Trading L P, a Illinois-based fund reported 13,863 shares. Hanseatic Management Service Inc invested in 5,149 shares or 0.44% of the stock. Advsrs Asset Management has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Amp Investors Ltd holds 36,428 shares or 0.02% of its portfolio. Gilder Gagnon Howe And Com Limited Liability Corporation accumulated 1.09 million shares or 1.16% of the stock. Winslow Evans And Crocker has 1,710 shares for 0.05% of their portfolio. Gateway Inv Advisers Ltd Liability reported 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Barclays Public Ltd Liability Company accumulated 0% or 50,112 shares.

Since April 16, 2018, it had 0 insider buys, and 3 insider sales for $7.07 million activity. Greenstreet Yvonne also sold $300,000 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, August 30. On Wednesday, July 25 the insider MARAGANORE JOHN sold $5.27 million. KEATING LAURIE also sold $164,178 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, April 16.

Analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report $-1.93 EPS on November, 6.They anticipate $0.59 EPS change or 44.03 % from last quarter’s $-1.34 EPS. After having $-1.83 EPS previously, Alnylam Pharmaceuticals, Inc.’s analysts see 5.46 % EPS growth. The stock increased 3.34% or $2.65 during the last trading session, reaching $81.95. About 746,277 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 19.20% since October 13, 2017 and is uptrending. It has outperformed by 3.58% the S&P500.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 8 analysts covering Alnylam Pharma (NASDAQ:ALNY), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Alnylam Pharma had 17 analyst reports since April 23, 2018 according to SRatingsIntel. The rating was maintained by Morgan Stanley with “Equal-Weight” on Friday, August 3. The firm has “Buy” rating by FBR Capital given on Wednesday, May 23. The firm has “Reduce” rating by Nomura given on Monday, August 13. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given on Monday, August 13 by Cowen & Co. Morgan Stanley maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, August 13 with “Equal-Weight” rating. The firm earned “Buy” rating on Wednesday, June 27 by Piper Jaffray. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Stifel Nicolaus on Thursday, September 13. Piper Jaffray maintained the shares of ALNY in report on Monday, April 23 with “Buy” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Stifel Nicolaus on Tuesday, August 7. The firm earned “Outperform” rating on Monday, August 13 by BMO Capital Markets.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $8.25 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The company??s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam restarts efforts to develop treatment for alpha-1 liver disease” on October 03, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on October 01, 2018, Seekingalpha.com published: “Alnylam reports positive results from Phase 1/2 study of lumasiran in patients with PH1” on October 04, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Businesswire.com and their article: “Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders in Recently Filed Class Action” published on October 08, 2018 as well as Seekingalpha.com‘s news article titled: “Alnylam facing patent dispute over Onpattro in Europe” with publication date: October 12, 2018.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>